{
  "retracted": false,
  "timestamp": 1501545600000,
  "updates": [
    {
      "timestamp": 1589019810711,
      "identifier": {
        "doi": "10.1016/j.ejca.2017.05.003"
      },
      "type": "erratum"
    }
  ],
  "identifier": {
    "doi": "10.1016/j.ejca.2017.01.024"
  },
  "publisher": "Elsevier BV",
  "title": "Corrigendum to ‘Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer’ [European Journal of Cancer 76 (2017) 36–44]"
}
